Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
| Autor: | Xinyi Li, Xin Li, Weihong Ge, Youjie Wang, Hao Wang, Chenxin Zeng |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Adult Cancer Research medicine.medical_specialty China Lung Neoplasms Afatinib Cost-Benefit Analysis Clinical Decision-Making Models Biological 03 medical and health sciences 0302 clinical medicine Gefitinib Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Aged Aged 80 and over Entire population business.industry General Medicine Exons Health Care Costs Middle Aged medicine.disease Survival Analysis Markov Chains Progression-Free Survival respiratory tract diseases First line treatment ErbB Receptors Regimen 030104 developmental biology Models Economic 030220 oncology & carcinogenesis Cost utility Mutation Non small cell Quality-Adjusted Life Years business medicine.drug |
| Zdroj: | Future oncology (London, England). 15(2) |
| ISSN: | 1744-8301 |
| Popis: | Aim: To evaluate the cost-utility of gefitinib and afatinib as first-line EGFR-mutated non-small-cell lung cancer treatments from the Chinese healthcare system perspective. Materials & methods: A Markov model was established, state transition probabilities were extracted from the LUX-Lung7 trial and utility values were from previous studies. The cost was extracted from local charge or relevant literature. Incremental cost–effectiveness ratio was calculated for intention-to-treat, EGFR exon 19 deletion (del19) and exon Leu858Arg (21L858R, L858R) muation subgroups. Results: For the entire population, the afatinib regimen afforded additional 0.29 quality-adjusted life years (QALYs). Incremental cost–effectiveness ratios were US$9820.41/QALY, US$18,529.65/QALY and US$1585.51/QALY for intention-to-treat, L858R and del19, respectively. Conclusion: First-line afatinib was more cost–effective than gefitinib for EFGR-mutated advanced non-small-cell lung cancer in China. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|